Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Clinical trial NCT05921760 · TERMINATED
Trial details
- NCT number
- NCT05921760
- Sponsor
- Servier Bio-Innovation LLC
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-23
- Primary completion
- 2024-11-21
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.